Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: Eight-year experience from single centre

Indian Journal of Cancer

Volumn 48, Issue 4, 2011, Pages 410-414

  Gupta, D ^a   Raina, V ^a   Rath, G K ^a   Shukla, N K ^a   Mohanti, B K ^a   Sharma, D N ^a  

^a Bhagwan Mahaveer Cancer Hospital and Research Center   (India)

Author keywords

Docetaxel; locally advanced breast cancer; neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLA; BREAST; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LOCALLY ADVANCED BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREMENOPAUSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84856837296     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.92258     Document Type: Article

References (32)

1. Ries LA, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, editors. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008. Available from: http://seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site.
2. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med 2003;49:222-8. (Pubitemid 37493414)
3. Chopra R. The Indian scene. J Clin Oncol 2001;19:106-11.
4. Nandkumar. National Cancer Registry Programme (ICMR). First All India report 2001-2002.
5. Valero VV, Buzdar AU, Hortobagyi GN. Locally advanced breast cancer. Oncologist 1996;1:8-17. (Pubitemid 126669366)
6. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 2002;20:3628-36. (Pubitemid 34983222)
7. DeLena M, Zucali R, Viganotti G, Valagussa P, Bonnadonna G. Combined chemotherapy radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-9. (Pubitemid 9025112)
8. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, et al. Neoadjuvant chemotharpy in the combined modality approach of locally advanced non metastatic breast cancer. Cancer Res 1987;47:3889-94. (Pubitemid 17105745)
9. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-8. (Pubitemid 13143147)
10. Powels TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary braest cancer. J Clin Oncol 1995;13:547-52.
11. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85. (Pubitemid 28363030)
12. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of Paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable braest cancer. J Clin Oncol 1999;17:3412-7. (Pubitemid 29517908)
13. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III Breast cancer. Oncology 1997;11:15-8. (Pubitemid 27357871)
14. Amat S, Bougnoux P, Penault-Lorca F, Fetissof F, Cure H, Kwiatkowski F, et al. Neoadjuvant Docetaxel for operable breast cancer induces a high pathological response and breast conservation rate. Br J Cancer 2003;88:1339-45. (Pubitemid 36606412)
15. Philip PA, Thatai LC, Vishnubhotla P, Biernat L, Flaherty L, LoRusso P, et al. Phase II study of Doxorubicin, Docetaxel and 5FU in patients with locally advanced breast cancer. Proc Am Soc Cli Oncol 2000;19:1309.
16. Lee YJ, Doliny P, Gomez-Fernandez C, Powell J, Reis I, Hurley J, et al. Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced braest cancer. Clin Breast Cancer 2004;5:371-6. (Pubitemid 40109645)
17. De Matties A, Nuzzo F, D'Aiuto G, Labonia V, Landi G, Rossi E, et al. Docetaxel plus Epirubicin as neoadjuvant treatment in patients with large operable or locally advanced braest cancer. Cancer 2002;94:895-901. (Pubitemid 34150842)
18. Raina V, Medhi K, Deo S, Shukla NK, Mohanti BK, Rath GK. Outcome of combined modality treatment of 412 cases of locally advanced breast cancer (LABC): Data from a tertiary cancer center in India. Breast Cancer Res Treat. 2007;106 Suppl 1:S1-350
19. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Dominguez ME, Rodriguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymphnodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-31. (Pubitemid 29090716)
20. Wolmark N, Wang J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: Nine year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Monogr 2001;30:96-102.
21. Deo SV, Bhutani M, Shukla NK, Raina V, Rath GK, Purkayasth J. Randomized trial comparing neoadjuvant vs adjuvant chemotherapy in locally advanced breast cancer (T4bN0-2M0). J Surg Oncol 2003;84:192-7. (Pubitemid 37484783)
22. vander Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Reasearch and Treatment of Cancer trial 10902. J Clin Oncol 2001;19: 4224-37. (Pubitemid 33081640)
23. Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, et al. Weekly Docetaxel is effective as neoadjuvant chemotherapy for stage II and stage III breast cancer. Efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003;9:686-92. (Pubitemid 36182601)
24. Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, et al. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 2005;94:279-84. (Pubitemid 41677633)
25. Valero V, Esteva FJ, Sahin AA. Phase II trial of neoadjuvant chemotherapy with doctaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/-tamoxifen in locally advanced breast cancer. Breast Cancer Res Treat 2000;64:9.
26. von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and Docetaxel. J Clin Oncol 1999;17:1999-2005. (Pubitemid 29318827)
27. Espinosa E, Morales S, Borrega P, Casas A, Madronal C, Machengs I, et al. Docetaxel and high dose Epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Chemo and Pharmacol 2004;54:546-52. (Pubitemid 40022251)
28. Baltali E, Altundag MK, Onat DA, Abbasoglu O, Ozisik Y, Guler N, et al. Neoadjuvant chemotherapy with Taxotere-epirubicin-5-fluorouracil (TEF) in loco regionally advanced breast cancer: A preliminary report. Tumori 2002;88:474-7. (Pubitemid 36193896)
29. Hirano A, Shimizu T, Imamura H, Watanabe O, Kinoshita J, Okabe T, et al. The combination of epirubicin plus Docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer. Anticancer Res 2006;26:581-4. (Pubitemid 43206020)
30. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding preoperative Docetaxel to preoperative Doxorubicin and Cyclophosphamide: Prelimnary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003;21:4165-74. (Pubitemid 46606185)
31. Kaufman M, Hortobagyi N, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An Update. J Clin Oncol 2006;24:1940-9. (Pubitemid 46638994)
32. Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A Tausch C, et al. Pathological complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony stimulating factor in operable breast cancer: Results of ABSCG-14 study. J Clin Oncol 2007;25:2012-8. (Pubitemid 46972785)